This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brucker-Davis, F. Articles by Weintraub, B. D. Search for Related Content PubMed PubMed Citation Articles by Brucker-Davis, F. Articles by Weintraub, B. D.

Thyrotropin-Secreting Pituitary Tumors: Diagnostic Criteria, Thyroid Hormone Sensitivity, and Treatment Outcome in 25 Patients Followed at the National Institutes of Health

Molecular and Cellular Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases (F.B.-D., M.C.S., B.D.W.); National Institute of Neurological Disorders and Stroke (E.H.O.); and the Department of Radiology (J.L.D.), National Institutes of Health, Bethesda, Maryland 20892

Address all correspondence to: Françoise Brucker-Davis, M.D., National Institutes of Health, Building 10, Room 8S235-B, 10 Center Drive, MSC 1770, Bethesda, Maryland 20892-1770.

We report a large series of 25 patients with TSH-secreting tumors (23 macroadenomas) followed at the NIH. Hyperthyroid symptoms were severe in 14 patients, mild in 8, and absent in 3. Patients were divided into 2 groups according to whether their thyroid had been treated (n = 11) or not (n = 14). In untreated patients, the classical diagnostic criteria (unresponsive TRH test, high -subunit, and high -subunit/TSH ratio) were present, respectively, in 10, 8, and 12 cases (sensitivity, 71%, 75%, and 83%; specificity, 96%, 90%, and 65%). In treated patients, the respective sensitivities of the TRH test, -subunit, and -subunit/TSH ratio were 64%, 90%, and 90%, and their specificities were 100%, 82%, and 73%. Studies of thyroid hormone action revealed no evidence of acquired resistance to thyroid hormone in TSH-secreting tumors. Apparent cure was achieved in 35% of cases by surgery alone and in 22% more by combined therapies. Three deaths occurred, including 1 from metastatic thyrotroph carcinoma. Six patients had residual tumor, with symptoms of hyperthyroidism controlled with octreotide in 5. The size and invasiveness of the tumor, duration of symptoms, and intensity of hyperthyroidism were the main prognostic factors. Thus, early diagnosis and treatment are the keys to a good outcome.

This article has been cited by other articles:

				E. S. Mittra, R. D. Niederkohr, C. Rodriguez, T. El-Maghraby, and I. R. McDougall Uncommon Causes of Thyrotoxicosis J. Nucl. Med., February 1, 2008; 49(2): 265 - 278. [Abstract] [Full Text] [PDF]

				T. Kienitz, M. Quinkler, C. J Strasburger, and M. Ventz Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature Eur. J. Endocrinol., July 1, 2007; 157(1): 39 - 46. [Abstract] [Full Text] [PDF]

				C Daousi, P M Foy, and I A MacFarlane Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours J. Neurol. Neurosurg. Psychiatry, January 1, 2007; 78(1): 93 - 95. [Abstract] [Full Text] [PDF]

				E. C. Nemergut, A. S. Dumont, U. T. Barry, and E. R. Laws Perioperative Management of Patients Undergoing Transsphenoidal Pituitary Surgery Anesth. Analg., October 1, 2005; 101(4): 1170 - 1181. [Abstract] [Full Text] [PDF]

				H. Furumoto, H. Ying, G. V. R. Chandramouli, L. Zhao, R. L. Walker, P. S. Meltzer, M. C. Willingham, and S.-Y. Cheng An Unliganded Thyroid Hormone {beta} Receptor Activates the Cyclin D1/Cyclin-Dependent Kinase/Retinoblastoma/E2F Pathway and Induces Pituitary Tumorigenesis Mol. Cell. Biol., January 1, 2005; 25(1): 124 - 135. [Abstract] [Full Text] [PDF]

				N. J. Sarlis, L. Gourgiotis, C. A. Koch, M. C. Skarulis, F. Brucker-Davis, J. L. Doppman, E. H. Oldfield, and N. J. Patronas MR Imaging Features of Thyrotropin-Secreting Pituitary Adenomas at Initial Presentation Am. J. Roentgenol., August 1, 2003; 181(2): 577 - 582. [Abstract] [Full Text] [PDF]

				S. Ando, N. J. Sarlis, E. H. Oldfield, and P. M. Yen Somatic Mutation of TR{beta} Can Cause a Defect in Negative Regulation of TSH in a TSH-Secreting Pituitary Tumor J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5572 - 5576. [Abstract] [Full Text] [PDF]

				S. Ando, N. J. Sarlis, J. Krishnan, X. Feng, S. Refetoff, M. Q. Zhang, E. H. Oldfield, and P. M. Yen Aberrant Alternative Splicing of Thyroid Hormone Receptor in a TSH-Secreting Pituitary Tumor Is A Mechanism for Hormone Resistance Mol. Endocrinol., September 1, 2001; 15(9): 1529 - 1538. [Abstract] [Full Text] [PDF]

				Confusion in an elderly patient: an uncommon diagnosis for such a common event Postgrad. Med. J., August 1, 2001; 77(910): 537d - 537. [Full Text] [PDF]

				P. Caron, S. Arlot, C. Bauters, P. Chanson, J.-M. Kuhn, M. Pugeat, R. Marechaud, C. Teutsch, E. Vidal, and P. Sassano Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2849 - 2853. [Abstract] [Full Text] [PDF]

				Pituitary Tumors in Children and Adolescents J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4317 - 4323. [Full Text]

				P. U. Freda and S. L. Wardlaw Diagnosis and Treatment of Pituitary Tumors J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3859 - 3866. [Full Text]